Uiree Jo1, Jin Roh2, Min Jeong Song3, Kyung-Ja Cho1, Wanlim Kim4, Joon Seon Song1. 1. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center Seoul, Republic of Korea. 2. Department of Pathology, Ajou University School of Medicine Suwon, Republic of Korea. 3. Department of Pathology, Kyung Hee University Hospital at Gangdong, Kyung Hee University, College of Medicine Seoul, Republic of Korea. 4. Department of Orthopedic Surgery, University of Ulsan College of Medicine, Asan Medical Center Seoul, Republic of Korea.
Abstract
INTRODUCTION: Myxoid liposarcoma (MLS) is a common lipogenic sarcoma, which is difficult to diagnose in small specimens. New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) is a cancer-testis antigen expressed in neoplastic tissue. In this study, NY-ESO-1 expression was assessed in various soft tissue tumors (STTs), and we also evaluated its diagnostic utility. METHODS: We included 434 cases of STTs for collection of clinicopathological data. Tissue microarrays were designed, and immunostaining for NY-ESO-1 was examined. We investigated the correlation between NY-ESO-1 expression and various clinicopathological parameters. We also evaluated the role of NY-ESO-1 as a diagnostic marker for MLS and its possible use in prognostication. RESULTS: Sixty-four of the 434 STTs (14.75%) were immunoreactive for NY-ESO-1, and the most frequent type of tumor in the NY-ESO-1 positive group was MLS (70.3%, 45/64), followed by synovial sarcoma (17.2%, 11/64). MLS showed 72.6% (45/62) immunopositivity for NY-ESO-1. The sensitivity and specificity of NY-ESO-1 expression for the diagnosis of MLS were 84.4% and 100%, respectively, compared to DDIT3 fluorescence in situ hybridization. When restricting analysis to the MLS (n=62), the NY-ESO-1 positive group had a poor overall survival (OS) rate (P=0.039). CONCLUSION: NY-ESO-1 was substantially and widely expressed in the majority of MLS cases. NY-ESO-1 positivity by IHC staining was also a predictor of a poor OS in patients with MLS. It is possible to use NY-ESO-1 for diagnosis and for predicting a prognosis in patients with MLS, and it may be used as a therapeutic target. AJTR
INTRODUCTION: Myxoid liposarcoma (MLS) is a common lipogenic sarcoma, which is difficult to diagnose in small specimens. New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) is a cancer-testis antigen expressed in neoplastic tissue. In this study, NY-ESO-1 expression was assessed in various soft tissue tumors (STTs), and we also evaluated its diagnostic utility. METHODS: We included 434 cases of STTs for collection of clinicopathological data. Tissue microarrays were designed, and immunostaining for NY-ESO-1 was examined. We investigated the correlation between NY-ESO-1 expression and various clinicopathological parameters. We also evaluated the role of NY-ESO-1 as a diagnostic marker for MLS and its possible use in prognostication. RESULTS: Sixty-four of the 434 STTs (14.75%) were immunoreactive for NY-ESO-1, and the most frequent type of tumor in the NY-ESO-1 positive group was MLS (70.3%, 45/64), followed by synovial sarcoma (17.2%, 11/64). MLS showed 72.6% (45/62) immunopositivity for NY-ESO-1. The sensitivity and specificity of NY-ESO-1 expression for the diagnosis of MLS were 84.4% and 100%, respectively, compared to DDIT3 fluorescence in situ hybridization. When restricting analysis to the MLS (n=62), the NY-ESO-1 positive group had a poor overall survival (OS) rate (P=0.039). CONCLUSION: NY-ESO-1 was substantially and widely expressed in the majority of MLS cases. NY-ESO-1 positivity by IHC staining was also a predictor of a poor OS in patients with MLS. It is possible to use NY-ESO-1 for diagnosis and for predicting a prognosis in patients with MLS, and it may be used as a therapeutic target. AJTR
Authors: A A Jungbluth; Y T Chen; E Stockert; K J Busam; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; L J Old Journal: Int J Cancer Date: 2001-06-15 Impact factor: 7.396
Authors: Theo Nicholaou; Lisa Ebert; Ian D Davis; Neil Robson; Oliver Klein; Eugene Maraskovsky; Weisan Chen; Jonathan Cebon Journal: Immunol Cell Biol Date: 2006-06 Impact factor: 5.126
Authors: Y T Chen; M J Scanlan; U Sahin; O Türeci; A O Gure; S Tsang; B Williamson; E Stockert; M Pfreundschuh; L J Old Journal: Proc Natl Acad Sci U S A Date: 1997-03-04 Impact factor: 11.205
Authors: Jessica A Hemminger; Amanda Ewart Toland; Thomas J Scharschmidt; Joel L Mayerson; William G Kraybill; Denis C Guttridge; O Hans Iwenofu Journal: Mod Pathol Date: 2012-08-31 Impact factor: 7.842
Authors: Makoto Endo; Marieke A de Graaff; Davis R Ingram; Simin Lim; Dina C Lev; Inge H Briaire-de Bruijn; Neeta Somaiah; Judith V M G Bovée; Alexander J Lazar; Torsten O Nielsen Journal: Mod Pathol Date: 2014-11-21 Impact factor: 7.842
Authors: Padmanee Sharma; Sacha Gnjatic; Achim A Jungbluth; Barbara Williamson; Harry Herr; Elisabeth Stockert; Guido Dalbagni; S Machele Donat; Victor E Reuter; Darren Santiago; Yao-Tseng Chen; Dean F Bajorin; Lloyd J Old Journal: Cancer Immun Date: 2003-12-18
Authors: Rita Alaggio; Cheryl M Coffin; Sharon W Weiss; Julia A Bridge; Josephine Issakov; Andre M Oliveira; Andrew L Folpe Journal: Am J Surg Pathol Date: 2009-05 Impact factor: 6.394
Authors: Elizabeth Shurell; Maria E Vergara-Lluri; Yunfeng Li; Joseph G Crompton; Arun Singh; Nicholas Bernthal; Hong Wu; Fritz C Eilber; Sarah M Dry Journal: Oncotarget Date: 2016-11-08